As BPIFB4 expression does not seem to arise as a new subclonal event after therapy (which would necessitate treatment only at recurrence) but rather represents a low-frequency clonal event in a primary tumor–initiating cell that is selected for survival through therapy, it should thus be targeted up-front. The gene discussed is BPIFB4; the disease is neoplasm.